|
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Clinical research trials and Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer. Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer clinical trial. Human subjects often receive the most effective healthcare possible for their Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer  Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
For Condition: stage 3B non-small cell lung cancer,recurrent non-small cell lung cancer,stage 4 non-small cell lung cancer
Status: No longer recruiting
Sponsor(s): Eastern Cooperative Oncology Group , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of carboplatin, gemcitabine, and exisulind in treating patients who have advanced non-small cell lung cancer.
Details: OBJECTIVES: - Determine the 18-month survival rate in patients with advanced non-small cell lung cancer treated with carboplatin, gemcitabine, and exisulind. - Determine the feasibility and toxicity of this regimen in these patients. - Determine the response rate, progression-free survival, and overall median survival of patients treated with this regimen. OUTLINE: Patients receive gemcitabine IV over 30 minutes on days 1 and 8 and carboplatin IV over 30 minutes on day 1. Chemotherapy repeats every 21 days for up to 6 courses. Patients also receive oral exisulind twice daily beginning on day 1 of course 1 and continuing until disease progression or unacceptable toxicity occurs. Patients are followed every 3 months for 2 years and then every 6 months for 2 years. PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study within 6 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed non-small cell lung cancer (NSCLC) - Unresectable stage IIIB (e.g., pleural effusion) not suitable for combined modality therapy OR - Stage IV - Prior brain metastases are allowed provided the following are true: - Patient completed radiotherapy and/or surgery at least 3 weeks prior to study - Objective evidence of resolution or significant improvement of brain lesions exists on follow-up CT scan or MRI - Patient is neurologically improved or stable PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-1 Life expectancy: - Not specified Hematopoietic: - Absolute granulocyte count at least 1,500/mm^3 - WBC at least 3,000/mm^3 - Hemoglobin at least 9 g/L - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.25 mg/dL - SGOT no greater than 1.5 times upper limit of normal Renal: - Creatinine no greater than 2.0 mg/dL OR - Creatinine clearance at least 50 mL/min Cardiovascular: - No prior uncontrolled cardiovascular disease - No hospitalization for acute myocardial infarction, arrhythmia, or congestive heart failure within the past 3 months Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective nonhormonal contraception - No serious active infection - No dementia or active psychoses - No other prior malignancy except nonmetastatic nonmelanoma skin cancer, carcinoma in situ of the cervix, or cancer curatively treated with surgery or small-field radiotherapy within the past 5 years PRIOR CONCURRENT THERAPY: Biologic therapy: - Not specified Chemotherapy: - No prior chemotherapy Endocrine therapy: - Not specified Radiotherapy: - See Disease Characteristics - At least 3 weeks since prior radiotherapy Surgery: - See Disease Characteristics Other: - At least 1 month since prior investigational agents - More than 7 days since prior aspirin, sulindac, cyclo-oxygenase-2 (COX-2) inhibitors, or nonsteroidal anti-inflammatory drugs (except ibuprofen or naproxen) - No concurrent sulindac or COX-2 inhibitors
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GregoryMasters, Study Chair, Evanston Northwestern Health Care
Veterans Affairs Medical Center - Pittsburgh
Pittsburgh, Pennsylvania, 15240-0001
United States
Stanford University Medical Center
Stanford, California, 94305-5408
United States
CCOP - Geisinger Clinic and Medical Center
Danville, Pennsylvania, 17822-2001
United States
Albert Einstein Clinical Cancer Center
Bronx, New York, 10461
United States
Veterans Affairs Medical Center - Palo Alto
Palo Alto, California, 94304-1290
United States
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
United States
CCOP - Ochsner
New Orleans, Louisiana, 70121
United States
Evanston Northwestern Health Care
Evanston, Illinois, 60201
United States
CCOP - Northern New Jersey
Hackensack, New Jersey, 07601
United States
Veterans Affairs Medical Center - Tennessee Valley Healthcare System - Nashville Campus
Nashville, Tennessee, 37212-2637
United States
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York City, New York, 10016
United States
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
United States
Burgess Health Center
Onawa, Iowa, 51040
United States
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
United States
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
United States
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232-6307
United States
MBCCOP - San Juan
San Juan, , 00927-5800
Puerto Rico
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
United States
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
United States
Veterans Affairs Medical Center - Indianapolis (Roudebush)
Indianapolis, Indiana, 46202
United States
CCOP - Christiana Care Health Services
Wilmington, Delaware, 19899
United States
CCOP - Illinois Oncology Research Association
Peoria, Illinois, 61602
United States
CCOP - Oklahoma
Tulsa, Oklahoma, 74136
United States
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309-1016
United States
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
United States
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, 07019
United States
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
United States
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
United States
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226-3596
United States
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
United States
CCOP - Ann Arbor Regional
Ann Arbor, Michigan, 48106
United States
Veterans Affairs Medical Center - Wichita
Wichita, Kansas, 67218
United States
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, 54301
United States
MBCCOP-Howard University Cancer Center
Washington D.C., District of Columbia, 20060
United States
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, 53705-2286
United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612-9497
United States
CCOP - Kalamazoo
Kalamazoo, Michigan, 49007-3731
United States
CCOP - Sioux Community Cancer Consortium
Sioux Falls, South Dakota, 57104
United States
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
United States
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
United States
Pretoria Academic Hospitals
Pretoria, , 0001
South Africa
Veterans Affairs Medical Center - Miami
Miami, Florida, 33125
United States
CCOP - Evanston
Evanston, Illinois, 60201
United States
CCOP - Toledo Community Hospital Oncology Program
Toledo, Ohio, 43623-3456
United States
CCOP - Marshfield Medical Research and Education Foundation
Marshfield, Wisconsin, 54449
United States
CCOP - Columbus
Columbus, Ohio, 43206
United States
Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242-1009
United States
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905
United States
CCOP - Wichita
Wichita, Kansas, 67214-3882
United States
Hahnemann University Hospital
Philadelphia, Pennsylvania, 19102-1192
United States
CCOP - Colorado Cancer Research Program, Inc.
Denver, Colorado, 80224
United States
Veterans Affairs Medical Center - New York
New York City, New York, 10010
United States
Veterans Affairs Medical Center - Tampa (Haley)
Tampa, Florida, 33612
United States
CCOP - Carle Cancer Center
Urbana, Illinois, 61801
United States
CCOP - Scottsdale Oncology Program
Scottsdale, Arizona, 85259-5404
United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
United States
MBCCOP-Our Lady of Mercy Cancer Center
Bronx, New York, 10466
United States
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
United States
Veterans Affairs Medical Center - Gainesville
Gainesville, Florida, 32608-1197
United States
University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, 35294-3300
United States
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15213-3489
United States
CCOP - Metro-Minnesota
St. Louis Park, Minnesota, 55416
United States
NSW Breast Cancer Institute
Westmead, New South Wales, 2145
Australia
Veterans Affairs Medical Center - Omaha
Omaha, Nebraska, 68105
United States
CCOP - Duluth
Duluth, Minnesota, 55805
United States
Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois, 60611-4494
United States
New England Medical Center Hospital
Boston, Massachusetts, 02111
United States
Veterans Affairs Medical Center - Brooklyn
Brooklyn, New York, 11209
United States
CCOP - Central Illinois
Decatur, Illinois, 62526
United States
CCOP - MainLine Health
Wynnewood, Pennsylvania, 19096
United States
CCOP - Cedar Rapids Oncology Project
Cedar Rapids, Iowa, 52403-1206
United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, 21231-2410
United States
University of Pennsylvania Cancer Center
Philadelphia, Pennsylvania, 19104
United States
Indiana University Cancer Center
Indianapolis, Indiana, 46202-5289
United States
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417-2399
United States
Veterans Affairs Medical Center - San Juan
San Juan, , 00927-5800
Puerto Rico
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-0001
United States
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
United States
Additional Information:
Study ID Numbers: CDR0000069467; E-E1501
Study Start Date:
Record last reviewed: April 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00041314
Other Stage 3b Non-Small Cell Lung Cancer Studies:
1. Paclitaxel in Treating Patients With Lung Cancer
2. Gemcitabine, Carboplatin, and Bortezomib in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
3. Photodynamic Therapy Plus Brachytherapy in Treating Patients With Lung Cancer
4. ZD1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
5. Hydroxyurea Plus Combination Chemotherapy in Patients With Non-small Cell Lung Cancer
Related Studies:
Other stage 3B non-small cell lung cancer Clinical Trials
Other Florida Clinical Trials
Other Tampa Clinical Trials
Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer
|
|
|
|
|
|
|
|
